Leukemia

Treatment shows promise in study of patients with relapsing disease

Published in Cancer Weekly, January 14th, 2003

Peptide vaccination of acute myelogenous leukemia patients can elicit highly active specific immunity against leukemia cells and induce remission, according to a study conducted by researchers at the University of Texas M.D. Anderson Cancer Center in Houston.

Results of this study were presented at the 44th annual meeting of the American Society of Hematology in Philadelphia.

"Researchers have been attempting to develop vaccines for cancer, including myeloid malignancies, for decades," according to Jeffrey Molldrem, MD, researcher from M.D. Anderson Cancer Center and study presenter. "We believe that the results of this pilot study show that...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-01-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry